文献速递药物不良反应与药物警戒特殊人群用药

重症患者利奈唑胺相关乳酸酸中毒的发生率、严重程度与预测因素

Linezolid-induced lactic acidosis in critically ill patients: A multicentre study of incidence, severity and predictors.
PubMed 文献 · Br J Clin Pharmacol · 2026-02-22

该多中心回顾性观察研究纳入2021年1月至2025年5月接受利奈唑胺治疗的成人ICU患者,共551例进行分析。乳酸酸中毒发生率为10.7%(n=59),平均起病时间4天,独立预测因素包括每日600 mg利奈唑胺、脓毒症、非肺炎感染及去甲肾上腺素使用。

要点

  • ICU患者利奈唑胺相关乳酸酸中毒发生率10.7%,多在中位4天早期出现
  • 每日600 mg利奈唑胺、脓毒症、非肺炎感染及去甲肾上腺素使用为独立预测因素
  • 高危患者应早期识别并加强监测以保障利奈唑胺安全使用

核心结论

  • 利奈唑胺相关乳酸酸中毒在ICU患者中较常见且常较严重,多于治疗早期发生。
  • 脓毒症、非肺炎感染及去甲肾上腺素使用被识别为关键危险因素。

研究设计与样本

  • 多中心回顾性观察研究,筛选904例成人ICU患者,最终纳入551例。
  • 纳入2021年1月至2025年5月接受利奈唑胺治疗的成人ICU患者,采用多变量logistic回归识别乳酸酸中毒预测因素。

主要发现

  • 551例纳入患者平均年龄56岁,男性占73.3%。
  • 乳酸酸中毒发生于10.7%(n=59),严重程度为中度22%、重度49%、危重29%,平均起病时间4天。
  • 独立预测因素:每日600 mg利奈唑胺(aOR=50.4;p=0.028)、脓毒症(aOR=2.61;p=0.042)、非肺炎感染(aOR=4.0;p=0.042)、去甲肾上腺素使用(aOR=3.56;p=0.005)。

临床怎么用

  • 对ICU中接受利奈唑胺治疗的高危患者应早期识别乳酸酸中毒并加强监测。
  • 对合并脓毒症、非肺炎感染或使用去甲肾上腺素者应提高警惕,促进利奈唑胺在重症人群中的安全使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Linezolid, a synthetic oxazolidinone for resistant gram-positive infections, is generally associated with mild adverse effects such as gastrointestinal disturbances, but more serious reactions like lactic acidosis (LA) have also been reported. LA may be more pronounced in critically ill patients; therefore, this study aims to determine the incidence, severity and predictors of linezolid-associated LA in this vulnerable population. METHODS: We conducted a retrospective observational study of adult ICU patients receiving linezolid from January 2021 to May 2025. Data on demographics, comorbidities, linezolid regimen, concomitant medications and laboratory values were collected. Multivariate logistic regression was used to identify predictors of LA. RESULTS: Of 904 patients screened, 551 were included (mean age 56 years; 73.3% male). LA occurred in 10.7% (n = 59) and was classified as moderate (22%), severe (49%) or critical (29%), with a mean onset of 4 days. Independent predictors of LA included linezolid at a daily dose of 600 mg (aOR = 50.4; p = 0.028), sepsis (aOR = 2.61; p = 0.042), infections other than pneumonia (aOR = 4.0; p = 0.042) and the use of norepinephrine (aOR = 3.56; p = 0.005). CONCLUSION: Linezolid-associated lactic acidosis is a frequent and often severe complication in ICU patients, typically developing early during therapy. Sepsis, non-pneumonia infections and norepinephrine use were identified as key risk factors. These findings highlight the need for early recognition and vigilant monitoring of high-risk patients to promote safer use of linezolid in critically ill populations.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Naseralallah L, Aboujabal B, Noureddine Z, et al. Linezolid-induced lactic acidosis in critically ill patients: A multicentre study of incidence, severity and predictors. Br J Clin Pharmacol. 2026. PMID: 41725266. doi:10.1002/bcp.70496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。